Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution

Sponsor
Milton S. Hershey Medical Center (Other)
Overall Status
Terminated
CT.gov ID
NCT01581905
Collaborator
(none)
98
1
2
15
6.5

Study Details

Study Description

Brief Summary

Approximately 600,000 women undergo hysterectomy each year in the United States, of which 12% are laparoscopic. The most common indications for hysterectomy are: symptomatic uterine leiomyomas (40.7%), endometriosis (17.7%), and prolapse (14.5%). The first total laparoscopic hysterectomy was performed by Reich et al in 1988. Many studies have proven that laparoscopic hysterectomy is associated with lower preoperative morbidity, shorter hospital stay, and shorter recovery times than abdominal hysterectomy. The literature has also shown the complication rates for laparoscopic cases are similar to open procedures in the hands of an experienced laparoscopic surgeon. The American Congress of Obstetricians and Gynecologists Committee on Gynecologic Practice state that laparoscopic hysterectomy is an alternative to abdominal hysterectomy for those patients in whom vaginal hysterectomy is not indicated or feasible. The ACOG Committee on Gynecologic Practice site multiple advantages of laparoscopic hysterectomy to abdominal hysterectomy including faster recovery, shorter hospital stay, less blood loss, and fewer abdominal wall/wound infections. Despite the recommendations of ACOG for a more minimally invasive approach, 66% of all hysterectomies are performed abdominally. Key reasons for the lag in utilization of laparoscopic techniques are the technical obstacles of performing minimally invasive hysterectomies. Robotic technology has emerged as a means to decrease the learning curve and increase the availability of minimally invasive surgery to patients. A current review of the literature reveals no randomized trials evaluating the efficacy of conventional laparoscopic hysterectomy vs. robot-assisted laparoscopic hysterectomy. The investigator's aim is to address this void.

The primary objective of this study is to determine whether Robot-Assisted Laparoscopic Hysterectomy is equivalent to Conventional Laparoscopic Hysterectomy with respect to operative time, blood loss, and hospital stay. The investigator's secondary objective was to assess the cost, morbidity, and mortality of each procedure.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Conventional Laparoscopic Hysterectomy (LH)
  • Procedure: Robot Assisted Hysterectomy
N/A

Detailed Description

See Above

Study Design

Study Type:
Interventional
Actual Enrollment :
98 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Randomized Controlled Trial Comparing Conventional Laparoscopic Hysterectomy With Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution
Study Start Date :
Mar 1, 2012
Actual Primary Completion Date :
Mar 1, 2013
Actual Study Completion Date :
Jun 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: LH Group

The LH Group includes individuals undergoing conventional laparoscopic hysterectomy, total or supracervical.

Procedure: Conventional Laparoscopic Hysterectomy (LH)
Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
Other Names:
  • LH Group
  • Active Comparator: RH Group

    The RH Group includes individuals undergoing Robot-Assisted laparoscopic hysterectomy, total or supracervical.

    Procedure: Robot Assisted Hysterectomy
    Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
    Other Names:
  • RH Group
  • Outcome Measures

    Primary Outcome Measures

    1. Operating Time [Operating time is measured on the day of surgery after completing the procedure.]

    Secondary Outcome Measures

    1. Estimated Blood Loss [Estimated blood loss will be measured on the day of surgery after completing the procedure.]

    2. Intraoperative Complications [Intraoperative complications will be measured on the day of surgery after completing the procedure.]

      Intraoperative complications include: injury to bladder, ureters, bowel, blood vessels,and nerves AND hemorrhage

    3. Perioperative Complications [Perioperative complications will be measured on the date of discharge from the hospital.]

      Perioperative complications include: urinary tract infections, urinary retention, ileus, myocardial infarction, atrial fibrillation, pulmonary edema, atelectasis, pneumonia, renal and cerebrovascular morbidity, thromboembolic complications (DVT and PE)

    4. Early Postoperative Complications [Early postoperative complications will be measured on the date of discharge from the hospital until two weeks after surgery, assessed up to 14 days post-operativley.]

      Early postoperative complications include: pulmonary, renal, and cerebrovascular morbidity, wound and vault complications (infection, breakdown, and dehiscence); septicemia, and thromboembolic complications (DVT, PE)

    5. Delayed Post-Operative Complications [Delayed post-operative complications will be measured from 2 weeks until 8 weeks after surgery, up to 56 days post-operatively.]

      Delayed post-operative complications include: incisional hernia formation, re-operation, vaginal evisceration

    6. Costs [Cost will be assessed 8 weeks after completion of the surgery, up to 56 days post-operatively.]

      Costs will include the costs of pre-operative care, surgery, post-operative care, and any post-operative complications.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Individuals recruited into this study will be patients presenting to the Urogynecology and Minimally Invasive Surgical Group for consultation for hysterectomy.

    Exclusion Criteria:Individuals who are not candidates for laparoscopic surgery

    • Medical Condition that does not allow pneumoperitoneum

    • Medical Condition that does not allow proper ventilation during anesthesia

    • Uterine size precluding access to the uterine artery

    • Pelvic Organ Prolapse amendable to a vaginal approach

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Penn State Milton S. Hershey Medical Center Hershey Pennsylvania United States 17033

    Sponsors and Collaborators

    • Milton S. Hershey Medical Center

    Investigators

    • Principal Investigator: Janis L Green, MD, Milton S. Hershey Medical Center
    • Study Director: Gerald J Harkins, MD, Milton S. Hershey Medical Center
    • Study Chair: Matthew Davies, MD, Milton S. Hershey Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Milton S. Hershey Medical Center
    ClinicalTrials.gov Identifier:
    NCT01581905
    Other Study ID Numbers:
    • 38824
    First Posted:
    Apr 20, 2012
    Last Update Posted:
    Jan 20, 2017
    Last Verified:
    Jan 1, 2017
    Keywords provided by Milton S. Hershey Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 20, 2017